Viralytics raises $4.7m to fund melanoma trial

By Staff Writers
Tuesday, 20 December, 2011

Viralytics has announced it has raised $4.7 million in a share purchase plan, which has raised the company’s cash reserves to over $8 million.

The fund raising was undertaken to coincide with the commencement of patient enrolment in the company’s US-based phase II melanoma trial.

The issue price of the shares was 30.84c and was based on the five day volume weighted price as of 14 December.

Viraltyics’ (ASX:VLA) share price dropped 5.5% to 34c by mid-afternoon, down from 36c at Monday’s close.

Content from other channels on our network

You see what others miss

Tapping into the labour mobility market to fill ongoing workforce gaps

NSW cracks down on illegal tanning with first two successful prosecutions

Australian hospital workers' mobile phones carry deadly superbugs — study reveals

Bupa to acquire Partnered Health's 68 primary care and three urgent care clinics

Demand increases for skilled sustainability professionals

Pilot program reduces food waste in SEQ

Yarra Valley Water to report net zero operational emissions

Recycling workers' lives at risk from hazardous waste

Biochar used for solar water purification

Blade innovation reduces the cost of slicing and dicing

Hygienic Design in Practice: Supporting Modern Food Production

From Manual Weighing to Intelligent Quality Control with METTLER TOLEDO's IND400

Siemens and IFS announce Industrial AI partnership

Drunken Sailor — Scaling Smart with Packserv Automation